SLC17A6 and Alzheimer disease: Especially in the light of aberrant VGLUT1 and VGLUT2 expression in human neurological diseases like Alzheimer’s disease (AD) (Kirvell et al., 2006) and Parkinson’s disease (PD) (Kashani et al., 2007), a study from 2015 made a valuable contribution by providing VGLUT1-3 mRNA and protein expression data from a wide range of human post mortem brain regions, e.g., the hippocampus (Vigneault et al., 2015).